ATM and colorectal carcinoma: The clinical application of Poly (ADP-ribose) polymerase (PARP) inhibition in CRC has gained attention based on data showing that PARP inhibitors (PARPi) improve prognosis when combined with chemotherapeutic agents such as platinum agents and irinotecan, and ATM deficiency increases sensitivity to PARP inhibition (85).